Argenx is a biotech company developing antibody-based therapies for autoimmune diseases. Its lead treatment, Vyvgart (efgartigimod), targets IgG antibodies to reduce harmful immune attacks. Patients with myasthenia gravis and other chronic conditions benefit from this innovative approach, which offers improved symptom control and quality of life through targeted, neonatal Fc receptor inhibition.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends